Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

被引：17
|
作者：
Oki, Yasuhiro [1 ]
Copeland, Amanda [1 ]
Romaguera, Jorge [1 ]
Fayad, Luis [1 ]
Fanale, Michelle [1 ]
Faria, Silvana de Castro [2 ]
Medeiros, L. Jeffrey [3 ]
Ivy, Percy [4 ]
Younes, Anas [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Imaging, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[4] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Rockville, MD USA
来源：
LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 05期
关键词：
PHASE-I TRIAL; CELL-CYCLE ARREST; ADVANCED CANCER; ALK EXPRESSION; KINASE; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; COMPLEX; AKT;
D O I：
10.3109/10428194.2011.631236
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：990 / 992
页数：3
相关论文
共 50 条
  • [1] Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma
    Younes, Anas
    Copeland, Amanda R.
    Romaguera, Jorge
    Fayad, Luis
    Fanale, Michelle
    Faria, Silvana de Castro
    Medeiros, L. Jeffrey
    Ivy, S. Percy
    BLOOD, 2009, 114 (22) : 1441 - 1441
  • [2] Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma
    Kefford, R.
    Millward, M.
    Hersey, P.
    Brady, B.
    Graham, M.
    Johnson, R. G.
    Hannah, A. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Potent Triazolothione Inhibitor of Heat-Shock Protein-90
    Feldman, Richard I.
    Mintzer, Bob
    Zhu, Daguang
    Wu, James M.
    Biroc, Sandra L.
    Yuan, Shendong
    Emayan, Kumar
    Chang, Zheng
    Chen, Deborah
    Arnaiz, Damian O.
    Bryant, Judi
    Ge, Xue Snow
    Whitlow, Marc
    Adler, Marc
    Polokoff, Mark A.
    Li, Wei-Wei
    Ferrer, Mike
    Sato, Takashi
    Gu, Jian-Ming
    Shen, Jun
    Tseng, Jih-Lie
    Dinter, Harald
    Buckman, Brad
    CHEMICAL BIOLOGY & DRUG DESIGN, 2009, 74 (01) : 43 - 50
  • [4] Therapeutic inhibition of heat shock protein-90 function in Hodgkin lymphoma
    Georgakis, G
    Li, Y
    Rassidakis, G
    Fayad, L
    Medeiros, L
    Younes, A
    ANNALS OF ONCOLOGY, 2005, 16 : 215 - 215
  • [5] Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
    Erlichman, Charles
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (06) : 861 - 868
  • [6] Antimyeloma activity of heat shock protein-90 inhibition
    Mitsiades, CS
    Mitsiades, NS
    McMullan, CJ
    Poulaki, V
    Kung, AL
    Davies, FE
    Morgan, G
    Akiyama, M
    Shringarpure, R
    Munshi, NC
    Richardson, PG
    Hideshima, T
    Chauhan, D
    Gu, XS
    Bailey, C
    Joseph, M
    Libermann, TA
    Rosen, NS
    Anderson, KC
    BLOOD, 2006, 107 (03) : 1092 - 1100
  • [7] CHARACTERIZATION OF THE HYDROPHOBIC REGION OF HEAT-SHOCK PROTEIN-90
    YAMAMOTO, M
    TAKAHASHI, Y
    INANO, K
    HORIGOME, T
    SUGANO, H
    JOURNAL OF BIOCHEMISTRY, 1991, 110 (01): : 141 - 145
  • [8] Secreted heat shock protein-90 (Hsp90) in wound healing and cancer
    Li, Wei
    Sahu, Divya
    Tsen, Fred
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2012, 1823 (03): : 730 - 741
  • [9] Inhibition of Heat Shock Protein-90 Attenuates Postangioplasty Intimal Hyperplasia
    Kassem, Mohammed M.
    DaCosta, Marry
    Muqri, Furqan
    Bruch, David
    Gahtan, Vivian
    Maier, Kristopher G.
    JOURNAL OF VASCULAR SURGERY, 2018, 68 (02) : E20 - E20
  • [10] EPITOPE MAPPING HUMAN HEAT-SHOCK PROTEIN-90 WITH SERA FROM INFECTED PATIENTS
    ALDUGHAYM, AM
    MATTHEWS, RC
    BURNIE, JP
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1994, 8 (01): : 43 - 48
12345